Impaired capacity for stimulated fibrinolysis in primary hypertension is restored by antihypertensive therapy

Hypertension

Volumn 47, Issue 4, 2006, Pages 686-691

  Ridderstråle, Wilhelm ^a   Ulfhammer, Erik ^a   Jern, Sverker ^a   Hrafnkelsdóttir, Thórdís ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiotensin antagonists; Antihypertensive agents; Calcium antagonists; Endothelium

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; FELODIPINE; LISINOPRIL; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE REGULATION; CEREBROVASCULAR ACCIDENT; CHI SQUARE TEST; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; FOREARM; HEART INFARCTION; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STUDENT T TEST; THROMBOSIS; TIME; BLOOD; BLOOD FLOW; BLOOD PRESSURE; BRACHIAL ARTERY; HEMODYNAMICS; INTRAARTERIAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; SECRETION; VASCULAR RESISTANCE; VASCULARIZATION; VASODILATATION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; FELODIPINE; FEMALE; FIBRINOLYSIS; FOREARM; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; INJECTIONS, INTRA-ARTERIAL; LISINOPRIL; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; SUBSTANCE P; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR RESISTANCE; VASODILATION;

EID: 33645831760     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000210540.35296.62     Document Type: Article

References (39)

1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
2. Lip GY, Blann AD. Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation. 2000;101:218-220.
3. Hrafnkelsdottir T, Wall U, Jern C, Jern S. Impaired capacity for endogenous fibrinolysis in essential hypertension. Lancet. 1998;352:1597-1598.
4. Hrafnkelsdottir T, Ottosson P, Gudnason T, Samuelsson O, Jern S. Impaired endothelial release of tissue-type plasminogen activator in patients with chronic kidney disease and hypertension. Hypertension. 2004;44:300-304.
5. Sjogren LS, Doroudi R, Gan L, Jungersten L, Hrafnkelsdottir T, Jern S. Elevated intraluminal pressure inhibits vascular tissue plasminogen activator secretion and downregulates its gene expression. Hypertension. 2000;35:1002-1008.
6. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost. 1995;74:429-436.
7. Lee AJ. The role of rheological and haemostatic factors in hypertension. J Hum Hypertens. 1997;11:767-776.
8. Jern C, Selin L, Jern S. Application of the perfused-forearm model to study release mechanisms of tissue-type plasminogen activator in man. Fibrinolysis. 1994;8:13-15.
9. Hrafnkelsdóttir T, Erlinge D, Jern S. Extracellular nucleotides ATP and UTP induce a marked acute release of tissue-type plasminogen activator in vivo in man. Thromb Haemost. 2001;85:875-881.
10. Wall U, Jern C, Jern S. High capacity for tissue-type plasminogen activator release from vascular endothelium in vivo. J Hypertens. 1997;15:1641-1647.
11. Newby DE, Wright RA, Ludlam CA, Fox KA, Boon NA, Webb DJ. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost. 1997;78:1242-1248.
12. Meijer P, Pollet DE, Wauters J, Kluft C. Specificity of antigen assays of plasminogen activator inhibitor in plasma: Innotest PAI-1 immunoassay evaluated. Clin Chem. 1994;40:110-115.
13. Ranby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Thromb Haemost. 1989;61:409-414.
14. van den Eijnden-Schrauwen Y, Kooistra T, de Vries RE, Emeis JJ. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood. 1995;85:3510-3517.
15. Ladenvall P, Johansson L, Jansson JH, Jem S, Nilsson TK, Tjarnlund A, Jern C, Boman K. Tissue-type plasminogen activator -7.351C/T enhancer polymorphism is associated with a first myocardial infarction. Thromb Haemost. 2002;87:105-109.
16. Jannes J, Hamilton-Bruce MA, Pilotto L, Smith BJ, Mullighan CG, Bardy PG, Koblar SA. Tissue plasminogen activator -7351C/T enhancer polymorphism is a risk factor for lacunar stroke. Stroke. 2004;35:1090-1094.
17. Bjorkman JA, Jern S, Jern C. Cardiac sympathetic nerve stimulation triggers coronary t-PA release. Arterioscler Thromb Vasc Biol. 2003;23:1091-1097.
18. Jern C, Seeman-Lodding H, Biber B, Winso O, Jern S. An experimental multiple-organ model for the study of regional net release/uptake rates of tissue-type plasminogen activator in the intact pig. Thromb Haemost. 1997;78:1150-1156.
19. Wall U, Jem S, Tengborn L, Jern C. Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm. Blood. 1998;91:529-537.
20. Brommer EJ. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards. Thromb Res. 1984;34:109-115.
21. Fox KA, Robison AK, Knabb RM, Rosamond TL, Sobel BE, Bergmann SR. Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. Circulation. 1985;72:1346-1354.
22. Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemost. 1994;72:588-594.
23. Minai K, Matsumoto T, Horie H, Ohira N, Takashima H, Yokohama H, Kinoshita M. Bradykinin stimulates the release of tissue plasminogen activator in human coronary circulation: effects of angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001;37:1565-1570.
24. Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension. 1999;34:285-290.
25. Sakata K, Shirotani M, Yoshida H, Urano T, Takada Y, Takada A. Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertension. Am Heart J. 1999;137:1094-1099.
26. de Boer A, Kluft C, Kroon JM, Kasper FJ, Schoemaker HC, Pruis J, Breimer DD, Soons PA, Emeis JJ, Cohen AF. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thromb Haemost. 1992;67:83-87.
27. Hrafnkelsdottir T, Gudnason T, Wall U, Jern C, Jern S. Regulation of local availability of active tissue-type plasminogen activator in vivo in man. J Thromb Haemost. 2004;2:1960-1968.
28. Matsumoto T, Minai K, Horie H, Ohira N, Takashima H, Tarutani Y, Yasuda Y, Ozawa T, Matsuo S, Kinoshita M, Horie M. Angiotensin-converting enzyme inhibition but not angiotensin II type 1 receptor antagonism augments coronary release of tissue plasminogen activator in hypertensive patients. J Am Coll Cardiol. 2003;41:1373-1379.
29. Pretorius M, Luther IM, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-Converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arterioscler Thromb Vasc Biol. 2005;25:2435-2440.
30. Labinjoh C, Newby DE, Pellegrini MP, Johnston NR, Boon NA, Webb DJ. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol. 2001;38:1402-1408.
31. Pretorius M, Rosenbaum D, Vaughan DE, Brown NI. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation. 2003;107:579-585.
32. Emeis II, van den Eijnden-Schrauwen Y, van den Hoogen CM, de Priester W, Westmuckett A, Lupu F. An endothelial storage granule for tissue-type plasminogen activator. J Cell Biol. 1997;139:245-256.
33. Ulfhammer E, Ridderstrale W, Andersson M, Karlsson L, Hrafnkelsdottir T, Jern S. Prolonged cyclic strain impairs the fibrinolytic system in cultured vascular endothelial cells. J Hypertens. 2005;23:1551-1557.
34. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens. 1998;16:447-456.
35. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, Salvetti A. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003;41:1281-1286.
36. von zur Muhlen B, Kahan T, Hagg A, Millgard I, Lind L. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens. 2001;19:1813-1818.
37. On YK, Kim CH, Oh BH, Lee MM, Park YB. Effects of angiotensin converting enzyme inhibitor and calcium antagonist on endothelial function in patients with essential hypertension. Hypertens Res. 2002;25:365-371.
38. Perticone F, Ceravolo R, Maio R, Ventura G, Iacopino S, Cuda G, Mastroroberto P, Chello M, Mattioli PL. Calcium antagonist isradipine improves abnormal endothelium-dependent vasodilation in never treated hypertensive patients. Cardiovasc Res. 1999;41:299-306.
39. Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A. Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients. Hypertension. 1997;30:1606-1612.